Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

Fig. 3

Correlations between clinical measures of rheumatoid arthritis (RA) signs and symptoms and patient-reported outcomes in overall RA population (placebo and CZP combined, intention-to-treat population). CRP C-reactive protein, CZP certolizumab pegol, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, FAS Fatigue Assessment Scale, HAQ-DI Health Assessment Questionnaire-Disability Index, JS joint score, MOS-SPI Sleep Problem Index II domain of the 12-item Medical Outcomes Study Sleep Scale, PtGA Patient Global Assessment of Disease Activity, RADAI Rheumatoid Arthritis Disease Activity Index, RAPID3 Routine Assessment of Patient Index Data 3, TS total score

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us